|Bid||2.3900 x 3100|
|Ask||2.4900 x 1100|
|Day's Range||2.3500 - 2.3900|
|52 Week Range||1.2600 - 15.2700|
|Beta (5Y Monthly)||-0.07|
|PE Ratio (TTM)||49.79|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Minerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizophrenia remains in effect.
The FDA has elected not to accept a new drug application from Minerva Neurosciences Inc., sending shares plummeting. Read this, and more, in the latest biotech news roundup, The Petri Dish.
Regulatory and pipeline updates from NERV and RLMD are the key highlights from the biotech sector during the past week.